Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Source: SeekingAlpha
2026-03-30 15:22:23 ET
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity March 30, 2026 1:00 PM EDT...
Read the full article on Seeking Alpha
For further details see:
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript
Biomea Fusion Inc.
NASDAQ: BMEA
BMEA Trading
20.47% G/L:
$1.5601 Last:
2,625,046 Volume:
$1.33 Open:
BMEA Latest News
March 31, 2026 07:00:00 am
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
March 30, 2026 05:02:42 pm
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
March 24, 2026 04:05:00 pm
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
BMEA Stock Data
$94,742,876
57,680,029
0.1%
21
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
